Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines
Takeshi Fukami
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Department of Thoracic Surgery, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorHiroshi Fukuhara
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorMasami Kuramochi
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorTomoko Maruyama
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorKana Isogai
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorMichiie Sakamoto
Department of Pathology, National Cancer Center Research Institute, Tokyo, Japan
Search for more papers by this authorShinichi Takamoto
Department of Thoracic Surgery, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Yoshinori Murakami
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Fax: +81-3-5565-9535
Tumor Suppression & Functional Genomics Project, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JapanSearch for more papers by this authorTakeshi Fukami
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Department of Thoracic Surgery, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorHiroshi Fukuhara
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorMasami Kuramochi
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorTomoko Maruyama
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorKana Isogai
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorMichiie Sakamoto
Department of Pathology, National Cancer Center Research Institute, Tokyo, Japan
Search for more papers by this authorShinichi Takamoto
Department of Thoracic Surgery, University of Tokyo, School of Medicine, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Yoshinori Murakami
Tumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan
Fax: +81-3-5565-9535
Tumor Suppression & Functional Genomics Project, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JapanSearch for more papers by this authorAbstract
We previously identified TSLC1, a tumor suppressor gene in human nonsmall cell lung cancer (NSCLC). TSLC1 belongs to immunoglobulin superfamily molecules and is involved in cell adhesion. Loss of TSLC1 expression was strongly correlated with the promoter hypermethylation in several NSCLC cell lines. Here, we examined the methylation status of the TSLC1 gene promoter in 48 primary NSCLC tumors by bisulfite SSCP in combination with bisulfite sequencing. Six CpG sites around the promoter regions were significantly methylated in 21 of 48 primary NSCLC tumors (44%). Promoter methylation was more likely to be observed in relatively advanced tumors with TNM classification of pT2, pT3 or pT4 (19 of 33, 58%) than in those with pT1 (2 of 15, 13%), suggesting that alteration of TSLC1 would be involved in the progression of human NSCLC. Loss of TSLC1 expression was also observed in 20 of 46 (43%) human cancer cell lines, including those from esophageal (3 of 3), gastric (8 of 9), ovarian (2 of 5), endometrial (2 of 2), breast (1 of 3), colorectal (2 of 8) and small cell lung cancers (2 of 10). Combined analysis of promoter methylation and the allelic state in these cell lines indicated that the TSLC1 gene was often silenced not only by mono-allelic methylation associated with loss of the other allele but also through bi-allelic methylation. These results suggest that alteration of TSLC1 would be involved in advanced NSCLC as well as in many other human cancers. © 2003 Wiley-Liss, Inc.
REFERENCES
- 1 Doyle R. Lung cancer in U.S. males. Sci Am 1997; 276: 28.
- 2 Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr Probl Cancer 1991; 15: 61–104.
- 3 Birrer MJ, Minna JD. Genetic changes in the pathogenesis of lung cancer. Annu Rev Med 1989; 40: 305–17.
- 4 Yuasa Y, Srivastava SK, Dunn CY, Rhim JS, Reddy EP, Aaronson SA. Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature 1983; 303: 775–9.
- 5 Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984; 223: 661–4.
- 6 Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990; 5: 1037–43.
- 7 Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491–4.
- 8 Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Gazdar AF, Minna JD. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990; 5: 1603–10.
- 9 Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992; 52: 4799–804.
- 10 Sachse R, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. DNA aberrations at the retinoblastoma gene locus in human squamous cell carcinomas of the lung. Oncogene 1994; 9: 39–47.
- 11 Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, Evans GA. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998; 282: 284–7.
- 12 Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, Landsvater RM, de Leij LF, Berendsen HH, Postmus PE, Poppema S, Buys CHCM. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987; 330: 578–81.
- 13 Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J, Light B, Haugen A, Mann DL, Trump BF, Harris CC. Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 1989; 86: 5099–103.
- 14 Iizuka M, Sugiyama Y, Shiraishi M, Jones C, Sekiya T. Allelic losses in human chromosome 11 in lung cancers. Genes Chromosomes Cancer 1995; 13: 40–6.
- 15
Tamura K,
Zhang X,
Murakami Y,
Hirohashi S,
Xu HJ,
Hu SX,
Benedict WF,
Sekiya T.
Deletion of three distinct regions on chromosome 13q in human non-small-cell lung cancer.
Int J Cancer
1997;
74:
45–9.
10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 16 Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami A, Ohki M, Cabin D, Frischmeyer P, Hunt P, et al. Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 1998; 95: 8153–8.
- 17 Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001; 27: 427–30.
- 18 Gomyo H, Arai Y, Tanigami A, Murakami Y, Hattori M, Hosoda F, Arai K, Aikawa Y, Tsuda H, Hirohashi S, Asakawa S, Shimizu N, et al. A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene IGSF4 in the LOH region of chromosome 11q23.2. Genomics 1999; 62: 139–46.
- 19 Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, Murakami Y. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002; 277: 31014–9.
- 20 Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, Shibuya T, Murakami M. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 2002; 62: 5129–33.
- 21 Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, Kitamura T, Reeves RH, et al. Promoter methylation of the TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002; 93: 605–9.
- 22 Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827–31.
- 23 Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998; 95: 8698–702.
- 24 Kawanishi M, Kohno T, Otsuka T, Adachi J, Sone S, Noguchi M, Hirohashi S, Yokota J. Allelotype and replication error phenotype of small cell lung carcinoma. Carcinogenesis 1997; 18: 2057–62.
- 25 Burri N, Chaubert P. Complex methylation patterns analyzed by single-strand conformation polymorphism. Biotechniques 1999; 26: 232–4.
- 26 Maekawa M, Sugano K, Kashiwabara H, Ushiama M, Fujita S, Yoshimori M, Kakizoe T. DNA methylation analysis using bisulfite treatment and PCR-single-strand conformation polymorphism in colorectal cancer showing microsatellite instability. Biochem Biophys Res Commun 1999; 262: 671–6.
- 27 Allinen M, Peri L, Kujala S, Lahti-Domenici J, Outila K, Karppinen SM, Launonen V, Winqvist R. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 2000; 34: 384–9.
- 28 Yang Q, Mori I, Shan L, Nakamura M, Nakamura Y, Utsunomiya H, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Sakurai T, Kakudo K. Inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. Am J Pathol 2001; 158: 299–303.